, which causes cancer through aberrant activation of the Ras/Raf/MEK/MAP kinase/ERK signaling pathway (MAP kinase pathway). [1] [2] [3] Several other uncommon mutations of the BRAF gene are also well characterized and may play an important role in the tumorigenesis of certain human cancers. [1] [2] [3] [4] [5] [6] A recent study reported an interesting T1790A point mutation in exon 15 of the BRAF gene in 10% of patients with childhood acute lymphoblastic leukemia (ALL). 7 This mutation is in codon 597, three codons upstream of codon 600 that carries the conventional T1799A mutation in the BRAF gene. The codon change (CTA to CAA) resulting from this new mutation causes a leucine-to-glutamine amino-acid change (L597Q) in the BRAF protein. Whether this fairly common BRAF L597Q in childhood ALL is functional and oncogenic remains to be determined.
In the present study, we generated the T1790A BRAF mutation through in vitro mutagenesis using wild BRAF in pEFm6 (which, together with the BRAF V600E construct, was a gift from Dr Richard Marais) as the template and appropriately designed primers and the Quick-Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutagenesis primers used were 5 0 -GTAAAAATAGGTGATTTTGGTCAAGCTACAGTGAA ATCTCGATGG-3 0 (forward) and 5 0 -CCATCGAGATTTCACTG TAGCTTGACCAAAATCACCTATTTTTAC-3 0 (reverse) (the nucleotide in italic and bold indicates the mutated site). We performed direct DNA sequencing to verify mutations generated. We first sought to determine the function of BRAF L597Q in activating the MAP kinase signaling pathway. As shown in Figure 1a , (left panel), transient transfection of NIH3T3 cells with these constructs resulted in expression of specific c-mycepitope-tagged BRAF, which was not seen with the control mock (parental NIH3T3 cells) and empty-vector transfections.
This was confirmed by western blotting using either c-myc epitope antibody or BRAF antibody (Figure 1a) . Correspondingly, dramatic increase in the phosphorylation of MEK and ERK occurred in serum-deprived cells expressing BRAF V600E and BRAF L597Q . Expression of the downstream signaling molecule cyclin D1, which is a key regulator of G 1 /S transition of the cell cycle 8 and is upregulated by the MAP kinase pathway, 9-11 was also increased. These molecular events were only minimally seen with the transfection and expression of the wild-type BRAF, BRAF WT and virtually absent with the control mock and emptyvector transfections. The activating ability was similar between the BRAF V600E and BRAF L597Q . All the molecular events in the MAP kinase signaling pathway triggered by transient transfection with the two BRAF mutants were seen also with their stable transfection (Figure 1a, right panel) . Although the expression efficiency of the two BRAF mutants in stably transfected cells was somehow uneven, high phosphorylation levels of MEK and ERK were seen with all the two mutants, while the abundantly expressed wild BRAF failed to induce phosphorylation of MEK and ERK in these growth factor-deprived (serum-starved) cells. These data suggest that the two BRAF mutants were both constitutively activated and, even at a low level of protein expression, were capable of saturating the phosphorylation sites of MEK and maximally activating it in the cell. These data suggest that, similar to T1799A, T1790A is an activating and gain-of-function BRAF mutation. The BRAF L597Q seems to be different than the previously described BRAF L597V mutant in cholangiocarcinoma and lung carcinoma in that the latter only showed a modest increase in kinase activity compared with the wild-type BRAF. To investigate further the oncogenic function of BRAF L597Q , we examined its transforming ability by comparing colony formation of various BRAF transfectants of NIH3T3 cells on soft agar. We found significant colony formation with the two activating mutants, BRAF V600E and BRAF L597Q , in a similar manner (Figures 1b and c) . No colony formation occurred with vector transfections (control). We also did not see colony formation with the BRAF WT transfectant. This was an expected result as the BRAF WT itself is not oncogenic and BRAF WT was unable to overactivate the MAP kinase pathway (Figure 1a) . These data demonstrated the transforming ability of the T1790A BRAF mutation and, together with its constitutive kinase activation of BRAF (Figure 1a) , demonstrated its oncogenic function.
In this study, we have for the first time explored the functionality of the T1790A BRAF mutation and demonstrated that the BRAF gene with this mutation is an oncogene. In addition to childhood ALL, 7 this mutation was reported also in cutaneous melanoma with a lower prevalence (3%). 12 The relative common occurrence (10%) of the T1790A mutation in childhood ALL suggests that this mutation plays an important role in a subpopulation of patients with this blood malignancy and may represent a novel therapeutic target for these patients.
